What is Waldenstrom macroglobulinaemia?
Waldenstrom macroglobulinaemia (WM) is a rare, slow-growing (low-grade) type of non-Hodgkin lymphoma. It starts in B lymphocytes that have partly matured towards plasma cells, the cells that normally make antibodies. These abnormal lymphoplasmacytic cells build up mainly in the bone marrow.
The lymphoma cells release large amounts of one abnormal antibody, called a monoclonal IgM protein or paraprotein. IgM is a very large molecule, which is where the name “macroglobulin” comes from. At high levels it can make the blood thick and sticky.
In medical terms, WM is a form of lymphoplasmacytic lymphoma (LPL) that involves the bone marrow and produces an IgM paraprotein of any level. About 95% of people with LPL have WM. The disease is named after the Swedish doctor Jan Waldenstrom, who first described it in 1944.
WM usually develops slowly over months or years, and many people have no symptoms when it is found. It cannot usually be cured, but modern treatment controls it well, and many people live with it for many years.
1. How common is it?
WM accounts for only about 1-2% of all blood cancers. In the UK, fewer than 400 people are diagnosed with it each year.
| Feature | Details |
|---|---|
| Typical age | Usually over 65; median age at diagnosis about 70 |
| Sex | About twice as common in men as in women |
| Ethnicity | More common in white people than in other groups |
| Family history | A close relative with WM, another B-cell lymphoma or chronic lymphocytic leukaemia raises the risk slightly |
| Main site | Bone marrow; lymph nodes and spleen less often |
2. Causes and risk factors
The exact cause of WM is not known. It is not infectious, and most people with it have no affected relatives.
| Risk factor | What it means |
|---|---|
| IgM MGUS | A harmless-looking IgM paraprotein without lymphoma; about 1-2% of people with it develop WM or a related disease each year |
| Family history | Relatives of people with WM have a higher risk of WM and related B-cell disorders, but the absolute risk stays low |
| Autoimmune and inflammatory conditions | For example Sjogren syndrome; linked with a modestly higher risk |
| Hepatitis C | Linked with lymphoplasmacytic lymphoma in some studies; doctors usually test for it |
| Older age and male sex | Risk rises with age and is higher in men |
Genetic changes in the lymphoma cells
The changes below are acquired during life. They are found only in the lymphoma cells and are not passed on to children.
| Change | How often | What it means |
|---|---|---|
| MYD88 L265P mutation | About 90-95% | Switches on growth signals (including through BTK); supports the diagnosis |
| CXCR4 mutations | About 30-40%, almost always with MYD88 | Higher IgM levels and more hyperviscosity; slower and less deep responses to BTK inhibitors, especially ibrutinib |
| Loss of part of chromosome 6q | About half of MYD88-mutated cases | Affects genes that control cell survival |
| ARID1A and CD79B mutations | About 17% and 8-15% | Less well understood |
| TP53 mutation or loss | Up to 10% | Linked with a poorer outcome |
| No MYD88 mutation (MYD88 wild-type) | About 5-10% | Higher risk of transformation and poorer survival |
The MYD88 mutation is also found in many people with IgM MGUS and in a small number of other lymphomas. On its own, therefore, it supports the diagnosis but does not prove it.
3. How does it look?
WM rarely causes visible changes, and many people look completely well. The disease is usually recognised through blood tests and a bone marrow sample.
3.1 On the body
- Pale skin and tiredness from anaemia, the most common finding.
- Bruising or small bleeding spots, and bleeding gums or nosebleeds.
- Swollen lymph nodes in the neck, armpits or groin, or an enlarged spleen, in about 1 in 5 people. The nodes are usually small and painless.
- Skin changes in the cold: bluish or white fingers, toes, nose or ears, a lace-like mottled rash or purple spots on the legs, caused by cryoglobulins or cold agglutinins.
- Changes at the back of the eye: in hyperviscosity, the eye doctor sees swollen, twisted retinal veins that look like a string of sausages, bleeding spots and sometimes swelling of the optic disc.
3.2 In blood tests
| Test | Typical finding |
|---|---|
| Serum protein electrophoresis | A sharp band (“spike”) of monoclonal protein |
| Immunofixation | Confirms that the paraprotein is IgM, usually with kappa light chains |
| IgM level | Raised; there is no minimum level for diagnosis |
| Full blood count | Anaemia is common; low platelets or white cells in more advanced disease |
| Serum viscosity | Normal is about 1.4-1.8; symptoms usually appear above about 4 |
| Beta-2 microglobulin and albumin | Used in prognostic scores |
3.3 Under the microscope
The bone marrow biopsy shows an infiltrate of small lymphocytes, plasmacytoid lymphocytes and plasma cells, often with increased mast cells. Some cells contain round antibody inclusions in the nucleus, called Dutcher bodies.
Flow cytometry and special stains show B cells that carry surface IgM and the markers CD19, CD20 and CD22. They are usually negative for CD5, CD10 and CD23, which helps to separate WM from chronic lymphocytic leukaemia, mantle cell lymphoma and follicular lymphoma. Testing for the MYD88 L265P mutation, and if possible CXCR4, is recommended.
4. Symptoms
Many people have no symptoms at diagnosis. When symptoms occur, they are caused either by the lymphoma cells in the marrow and organs, or by the IgM protein itself.
4.1 Symptoms caused by lymphoma cells
| Symptom | Cause |
|---|---|
| Tiredness, weakness, breathlessness | Anaemia, the most common symptom of WM |
| Infections | Low white cell count and low levels of normal antibodies |
| Bruising and bleeding | Low platelets, or IgM interfering with clotting |
| Fullness or discomfort in the abdomen | Enlarged spleen or liver |
| Lumps in the neck, armpit or groin | Swollen lymph nodes |
| Fever, night sweats, weight loss | B symptoms; may also signal faster-growing disease |
4.2 Symptoms caused by the IgM protein
| Problem | Typical symptoms |
|---|---|
| Hyperviscosity syndrome | Nosebleeds, bleeding gums, blurred or lost vision, headache, dizziness, ringing in the ears, drowsiness or confusion, breathlessness |
| Peripheral neuropathy | Tingling, numbness or unsteadiness, usually starting in both feet; affects about 1 in 4 people |
| Cryoglobulinaemia | Painful, blue or white fingers in the cold, purple rash on the legs, skin ulcers |
| Cold agglutinin disease | Anaemia and dark urine after cold exposure, blue fingertips or ear lobes |
| AL amyloidosis | Swollen legs, frothy urine, breathlessness, numbness; amyloid can damage the heart, kidneys and nerves |
Symptomatic hyperviscosity is a medical emergency. It needs urgent plasma exchange followed by treatment of the lymphoma.
4.3 Bing-Neel syndrome
In about 1 in 100 people, WM cells spread to the brain or spinal cord. This is called Bing-Neel syndrome. It can cause headaches, weakness, numbness, unsteadiness, seizures or changes in thinking.
When to see a doctor
See a doctor if you have ongoing tiredness, repeated nosebleeds, changes in your vision, numbness or tingling in your feet, or unexplained weight loss. If you already know you have an IgM paraprotein, report any of these symptoms promptly.
5. Diagnosis
WM is often suspected when a routine blood test shows anaemia or a high protein level. The diagnosis is based on two findings: a monoclonal IgM protein in the blood and bone marrow involvement by lymphoplasmacytic lymphoma.
5.1 Tests
| Test | Purpose |
|---|---|
| Bone marrow aspirate and biopsy | Confirms the diagnosis and shows how much of the marrow is involved |
| MYD88 and CXCR4 testing | Supports the diagnosis and helps choose treatment |
| Blood tests | Blood count, IgM and other antibodies, kidney and liver function, LDH, albumin, beta-2 microglobulin |
| Virus tests | Hepatitis B and C and HIV, before treatment |
| Serum viscosity and eye examination | If IgM is high or there are symptoms of hyperviscosity |
| CT scan | Checks lymph nodes, liver and spleen, usually when treatment is planned |
| Tests for complications | Cryoglobulins, cold agglutinins, nerve antibodies (anti-MAG), urine protein and heart markers for amyloidosis |
| MRI and lumbar puncture | If Bing-Neel syndrome is suspected |
5.2 Related conditions
| Condition | Definition |
|---|---|
| IgM MGUS | IgM paraprotein below 30 g/L, less than 10% lymphoplasmacytic cells in the marrow and no symptoms |
| Smouldering (asymptomatic) WM | IgM of 30 g/L or more, or 10% or more marrow involvement, but no symptoms or organ damage |
| Symptomatic WM | WM causing symptoms or complications that need treatment |
The WHO 5th edition and the ICC classifications, both from 2022, keep WM as the main form of lymphoplasmacytic lymphoma. Both separate it from IgM MGUS and from rare forms of LPL that make IgG or IgA instead of IgM.
6. Staging and prognosis scores
WM does not use the usual lymphoma stages, because it is almost always in the bone marrow. Instead, doctors use prognostic scores based on age and blood tests.
6.1 IPSSWM
The International Prognostic Scoring System for WM (IPSSWM) was published in 2009. It gives one point for each of five factors:
| Factor | Adverse value |
|---|---|
| Age | Over 65 |
| Haemoglobin | 11.5 g/dL or less |
| Platelets | 100 x 10^9/L or less |
| Beta-2 microglobulin | Over 3 mg/L |
| Monoclonal IgM | Over 70 g/L (7 g/dL) |
| Risk group | Definition | 5-year survival in the original study |
|---|---|---|
| Low | No more than one factor, not counting age | 87% |
| Intermediate | Two factors, or age over 65 alone | 68% |
| High | More than two factors | 36% |
6.2 Revised IPSSWM
The revised IPSSWM (2019) uses age, beta-2 microglobulin, albumin and LDH. Age 66-75 scores 1 point and age 76 or over scores 2 points. Beta-2 microglobulin of 4 mg/L or more, albumin below 3.5 g/dL and LDH of 250 IU/L or more each score 1 point.
| Group | Points | Risk of death from WM within 3 years |
|---|---|---|
| Very low | 0 | About 0% |
| Low | 1 | About 10% |
| Intermediate | 2 | About 14% |
| High | 3 | About 38% |
| Very high | 4-5 | About 48% |
These scores estimate outlook, but experts do not recommend choosing treatment by score alone. CXCR4 and MYD88 status are not part of the scores, but they help predict how well BTK inhibitors will work.
7. Treatment
7.1 When to treat
People without symptoms are monitored with regular blood tests (watch and wait). Starting treatment early does not help them live longer, and some never need treatment.
Treatment is started when WM causes problems, such as:
- Haemoglobin of 10 g/dL or less, or platelets below 100 x 10^9/L
- Symptomatic hyperviscosity
- Troublesome neuropathy, cryoglobulinaemia, cold agglutinin anaemia or amyloidosis
- Large or symptomatic lymph nodes or spleen
- Fever, night sweats or weight loss
A high IgM level alone is not usually a reason to treat. Very high levels with a risk of hyperviscosity are an exception.
7.2 First-line treatment options
| Treatment | How it is given | Main advantages | Main side effects |
|---|---|---|---|
| Bendamustine + rituximab (BR) | Drip on 2 days every 4 weeks, usually 4-6 cycles | Fixed duration; deep, lasting remissions; preferred when rapid control is needed | Low blood counts, infections, rash, tiredness |
| Dexamethasone, rituximab, cyclophosphamide (DRC) | Tablets and drip, every 3 weeks for 6 cycles | Gentle, fixed duration; for less fit people with slower disease | Low blood counts, high blood sugar from steroids |
| Zanubrutinib | Tablets, 160 mg twice daily or 320 mg once daily, continued long term | Oral; fewer heart rhythm problems than ibrutinib; works well in CXCR4-mutated disease | Low neutrophils, bruising, infections, high blood pressure |
| Ibrutinib, alone or with rituximab | Tablets, 420 mg once daily, continued long term | Oral; the first drug approved for WM | Atrial fibrillation, bleeding, high blood pressure, diarrhoea |
| Bortezomib-based regimens | Injections, usually with dexamethasone and rituximab | Useful in amyloidosis or kidney problems | Nerve damage, so avoided if neuropathy is present |
| Rituximab alone | Drip, weekly or in blocks | Gentle option where other treatment is unsuitable | Slow, modest responses; temporary IgM “flare” in up to half |
BTK inhibitors block a signal that WM cells need to survive. Ibrutinib was approved in the US in 2015 and zanubrutinib in the US and EU in 2021. Acalabrutinib has also been studied in WM.
In the phase 3 ASPEN trial, zanubrutinib and ibrutinib controlled WM equally well. Zanubrutinib caused less atrial fibrillation and fewer side effects leading to stopping treatment. Very good partial responses were seen in 28% versus 19% of patients, a difference that was not statistically significant.
In the iNNOVATE trial, adding ibrutinib to rituximab greatly improved disease control. At 30 months, 82% of patients given both drugs were free of progression, compared with 28% with rituximab alone. Ibrutinib also made an IgM flare much less likely.
BTK inhibitors are taken until they stop working or cause problems. Stopping them suddenly can cause a quick rise in IgM and withdrawal symptoms such as fever and aches.
Rituximab can cause a temporary rise in IgM, called an IgM flare. If IgM is above about 40 g/L, rituximab is often delayed for 1-3 cycles or plasma exchange is done first.
7.3 Plasma exchange (plasmapheresis)
Plasma exchange removes IgM from the blood and quickly relieves hyperviscosity. Two or three sessions usually lower the IgM level by 30-60%.
The effect is temporary, so it must always be followed by treatment of the lymphoma. Red cell transfusions should be avoided until after plasma exchange, because they can make the blood even thicker.
7.4 Relapsed or refractory WM
If WM returns after a long remission, the first treatment may be used again. If it returns early, a treatment from a different class is chosen.
| Option | Notes |
|---|---|
| Chemoimmunotherapy (BR or DRC) | After BTK inhibitor failure, or after a long remission from previous chemoimmunotherapy |
| BTK inhibitor | If not used before; switching from ibrutinib to zanubrutinib is possible if side effects were the problem |
| Pirtobrutinib | A non-covalent BTK inhibitor that can work after covalent BTK inhibitors |
| Proteasome inhibitors | Bortezomib, carfilzomib or ixazomib with rituximab and dexamethasone |
| Venetoclax | A BCL2 inhibitor with good activity in trials; not specifically approved for WM |
| Autologous stem cell transplant | Rarely used; for selected younger patients with relapsed disease that still responds to chemotherapy |
| Clinical trials | New drugs and combinations |
7.5 Supportive care
- Hepatitis B: people with past infection usually take antiviral tablets such as entecavir during rituximab treatment.
- Vaccinations: yearly flu, pneumococcal and COVID-19 vaccines are recommended. Live vaccines should be avoided.
- BTK inhibitor safety: blood pressure and heart rhythm are checked, and the drug is paused around surgery because of bleeding risk.
- Infections: antibiotics or antibody replacement (immunoglobulin) may be used for repeated infections.
8. Treatment response
Response is measured mainly by the fall in the IgM level and by improvement in symptoms and blood counts.
| Response | Definition (simplified) |
|---|---|
| Complete response | IgM normal, no paraprotein on immunofixation and no WM in the marrow |
| Very good partial response | IgM down by 90% or more |
| Partial response | IgM down by 50-89% |
| Minor response | IgM down by 25-49% |
Complete responses are uncommon with BTK inhibitors. A deep response is not always needed; good control of symptoms and blood counts is the main goal.
9. Prognosis
WM is usually a long-lasting, slow-growing disease. Survival has improved steadily as treatment has improved.
- In a large US registry study, median survival rose from about 6 years for people diagnosed in the 1990s to about 8 years for those diagnosed in 2001-2010. Many people now live considerably longer.
- WM is mainly a disease of older people, and many die of unrelated causes.
- Outlook is better for younger people with a low prognostic score and normal albumin, LDH and beta-2 microglobulin.
- Transformation to an aggressive lymphoma, usually diffuse large B-cell lymphoma, is uncommon, affecting a few per cent of people over many years. It is treated like diffuse large B-cell lymphoma, for example with R-CHOP.
- MYD88 wild-type disease and TP53 changes are linked with a poorer outlook.
10. Follow-up and living with WM
10.1 Follow-up
People on watch and wait are usually seen every 3-12 months, depending on how stable the IgM level and blood counts are. During and after treatment, visits include a blood count, IgM level and a check for symptoms.
Scans are repeated only when needed, for example if new lumps or symptoms appear. A new biopsy is taken if transformation is suspected.
10.2 Everyday life
- Report nosebleeds, vision changes, new numbness or tingling, fevers and unexplained weight loss promptly.
- Keep warm in cold weather if you have cryoglobulins or cold agglutinins, and protect your hands and feet.
- Tell every doctor and dentist that you take a BTK inhibitor, and check before starting new medicines, including blood thinners and some antibiotics and antifungals.
- Gentle regular exercise, a balanced diet and enough sleep help with tiredness.
- Patient organisations such as the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) and Lymphoma Action offer information and peer support.
Resources
- Owen, R.G. et al. (2003) ‘Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia’, Seminars in Oncology, 30(2), pp. 110-115.
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
- Treon, S.P. et al. (2012) ‘MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia’, New England Journal of Medicine, 367(9), pp. 826-833.
- Treon, S.P. et al. (2020) ‘Genomic landscape of Waldenstrom macroglobulinemia and its impact on treatment strategies’, Journal of Clinical Oncology, 38(11), pp. 1198-1208.
- Morel, P. et al. (2009) ‘International prognostic scoring system for Waldenstrom macroglobulinemia’, Blood, 113(18), pp. 4163-4170.
- Kastritis, E. et al. (2019) ‘A revised international prognostic score system for Waldenstrom’s macroglobulinemia’, Leukemia, 33(11), pp. 2654-2661.
- Tam, C.S. et al. (2020) ‘A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study’, Blood, 136(18), pp. 2038-2050.
- Dimopoulos, M.A. et al. (2018) ‘Phase 3 trial of ibrutinib plus rituximab in Waldenstrom’s macroglobulinemia’, New England Journal of Medicine, 378(25), pp. 2399-2410.
- Buske, C. et al. (2023) ‘Report of consensus panel 1 from the 11th International Workshop on Waldenstrom’s Macroglobulinemia on management of symptomatic, treatment-naive patients’, Seminars in Hematology, 60(2), pp. 73-79.
- Kastritis, E. et al. (2018) ‘Waldenstrom’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 29(Suppl 4), pp. iv41-iv50.
- Castillo, J.J. et al. (2015) ‘Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database’, British Journal of Haematology, 169(1), pp. 81-89.
- Lymphoma Action (2026) Lymphoplasmacytic lymphoma and Waldenstrom’s macroglobulinaemia. Available at: https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/lymphoplasmacytic-lymphoma-and-waldenstroms-macroglobulinaemia (Accessed: October 2026).
Prepared by the editorial team, October 2026.